BACK TO NEWS
Gero expands its team to scale human-genetics-driven target discovery
New appointments across human genetics, AI, translational science, and business development strengthen Gero’s target discovery capabilities and pharmaceutical partnerships
Partnership Release
Event
News
Publication
November 17, 2026

SINGAPORE, Nov. 17, 2026 — Gero, a biotechnology company developing physics-based AI models of longitudinal human health data to discover therapeutic targets for chronic diseases and aging, today announced an expansion of its scientific and commercial leadership, including the appointment of Jason Brown as head of business development.

Lack of efficacy is the leading cause of clinical failure, and drug mechanisms with human genetic support are 2.6 times more likely to succeed in the clinic. The expanded team strengthens Gero’s ability to identify and prioritize therapeutic targets supported by human genetic evidence and advance discovery programs with pharmaceutical partners.

The expansion follows Gero’s $17 million financing announced in June 2026, bringing its total equity funding to $34 million. The financing supports preclinical development of its pipeline and the growth of its pharmaceutical partnerships. This year Gero was named a World Economic Forum Technology Pioneer and included on the Forbes Asia 100 to Watch list.

“Gero has built a strong portfolio of targets discovered in human data, which have already been licensed by pharma, and we look forward to our expanded team’s expertise in advancing this portfolio into new partnerships and programs,” said Peter Fedichev, Ph.D., co-founder and CEO of Gero. “For pharma, that means targets grounded in human genetic evidence from millions of patients, which lowers the risk of failure in the clinic and gives each program a stronger chance of reaching patients.”

Jason Brown, Ph.D., head of business development, leads partnering and out-licensing for Gero’s target discovery and generative chemistry platforms, as well as its therapeutic programs. His leadership experience spans pharmaceutical R&D, biotechnology and discovery services, including roles at Pfizer and Evotec, where he partnered AI-enabled drug discovery platforms with pharmaceutical companies. Most recently, he served as chief business officer at IMU Biosciences, leading business development for an AI-driven immune profiling technology built on large-scale human immune data. “Pharma partners are looking for targets and programs supported by causal human biology,” Brown said. “Gero has the data, AI analytics and the team to deliver them.”

Sodbo Sharapov, Ph.D., statistical genetics lead, brings 12 years of experience applying human genetics to disease biology and drug discovery. At the Human Technopole Genomics Center in Milan, he led drug discovery and repurposing analyses and contributed to large-scale fine-mapping and colocalization pipelines that identify genes and proteins implicated in disease. His research has mapped genetic architecture across immune-cell gene expression, the human plasma proteome and AI-derived cardiac MRI traits.

Irene López Santiago, statistical geneticist and machine learning scientist, specializes in identifying the genes most likely to drive disease. At OpenTargets (EMBL-EBI), she was the primary developer of the Locus-to-Gene (L2G) model, which prioritizes likely causal genes from genetic association signals, and the open-source Gentropy post-GWAS framework. Her expertise strengthens Gero’s genetics-led target prioritization.

Jérémie Zumer, Ph.D., AI/ML translational science lead, leads development efforts for Gero’s next-generation longitudinal health models, drawing on expertise in deep learning and computational biology. At IONLACE, he led a cross-functional team developing an AI-enabled nanobody design platform that achieved in vitrobinding success rates approximately 100 times higher than the methods used for comparison. Previously, he led AI model development at Maluuba, later acquired by Microsoft, and worked at Microsoft Research, contributing to patented technology and models deployed at scale. He holds a Ph.D. in bioinformatics from the Université de Montréal and trained in deep learning at Mila.

Artem Kiselev, Ph.D., senior translational scientist, drives the translational evaluation of therapeutic targets by combining experimental biology, bioinformatics and multi-omics. Artem has more than 15 years of experience in molecular and cell biology, genetic engineering and computational analysis. At Michigan State University, he discovered a previously undescribed activation state of epidermal Langerhans cells using single-cell transcriptomics, flow cytometry and intravital imaging. His broader experience includes clinical NGS for rare genetic disorders and development of bioinformatics and multi-omics analysis pipelines.

Mina Nguyen, head of communications, leads Gero’s corporate positioning, media relations, and investor and pharmaceutical partner communications. She previously held senior communications roles at Pfizer Oncology, Seagen and Ionis Pharmaceuticals, leading communications in oncology medicines through pivotal clinical milestones and regulatory approvals in the United States and Europe. Her experience spans scientific and product communications, corporate reputation and executive positioning in biopharmaceutical companies.

###

About Gero

Gero is a techbio company developing physics-based AI longitudinal foundation models of human health to discover novel therapeutic targets for chronic diseases and aging. Drawing on 250 million medical history records, population genetics, and multi-omics, Gero’s platform identifies the underlying drivers of disease and prioritizes therapeutic targets supported by human evidence. Its complementary generative chemistry platform designs small molecules against challenging targets.

Gero is advancing proprietary and partnered therapeutic programs across metabolic disease, neuroinflammation, oncology, and aging-related conditions. Its pharmaceutical collaborations have included Pfizer and Chugai Pharmaceutical, a member of the Roche Group, which licensed Gero-discovered therapeutic targets.

Headquartered in Singapore, Gero operates in the United Kingdom and the United States. For more information, visit www.gero.ai and follow Gero on LinkedIn and X at @hacking_aging.

Media contact: media@gero.ai

‍

LINK TO ARTICLE
RECENT NEWS
Press Release
Press Release
Press Release
News
Gero expands its team to scale human-genetics-driven target discovery
November 17, 2026
News
Press Release
News
News
Gero Earned an Honorable Mention at the Nebius AI Discovery Awards 2026
July 3, 2026
Press Release
Press Release
Press Release
News
Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines
June 17, 2026
News
Press Release
News
News
Gero Named World Economic Forum 2026 Technology Pioneer for Advancing the Physics of Aging in Drug Discovery
June 10, 2026